ABT Stock Risk & Deep Value Analysis
Abbott Laboratories
DVR Score
out of 10
The Bottom Line on ABT
We analyzed Abbott Laboratories using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ABT through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
ABT Stock Risk Analysis
Overall Risk
Moderate
Financial Risk
Low
Market Risk
Low
ABT Deep Value Analysis
Compare ABT to Similar Stocks
See how Abbott Laboratories stacks up against related companies in our head-to-head analysis.
ABT Red Flags & Warning Signs
- âš
Major product recall or safety issue affecting key franchises
- âš
Increased competitive pressure in CGM or structural heart markets
- âš
Significant changes in global healthcare reimbursement policies
- âš
Adverse outcomes in late-stage clinical trials for pipeline products
Unlock ABT Red Flags & Risk Warnings
Create a free account to see the full analysis
ABT Competitive Moat Analysis
Sign in to unlockMoat Rating
Wide
Moat Trend
Stable
Moat Sources
4 Identified
Abbott's moat is highly durable, driven by continuous innovation, a vast portfolio of patented products, the high cost and regulatory hurdles for competitors, and strong brand loyalty for its consumer-facing products. Its integrated solutions in diagnostics and medical devices create high switching costs for healthcare providers.
ABT Competitive Moat Analysis
Sign up to see competitive advantages
ABT Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated late April 2026)
- •Potential new product approvals in medical devices (e.g., next-gen FreeStyle Libre, structural heart devices)
- •Continued strong performance in core diagnostics and medical device segments
Medium-Term (6-18 months)
- •Expansion of FreeStyle Libre indications and market penetration in emerging economies
- •Rollout of new Alinity diagnostic system upgrades and increased adoption
- •Strategic tuck-in acquisitions to bolster pipeline or market share in specific niches
Long-Term (18+ months)
- •Leveraging aging global demographics and rising prevalence of chronic diseases
- •Leadership in personalized healthcare and data-driven diagnostics
- •Expansion into new therapeutic areas through R&D or M&A
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
ABT Bull Case: What Could Go Right
- ✓
Sustained acceleration in FreeStyle Libre revenue growth and new market penetration
- ✓
Pipeline updates and regulatory approvals for next-generation medical devices
- ✓
Any significant shifts in organic sales growth rates for its core segments
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.
